Coverage
-
July 30, 2018
Shareholders in Israeli pharmaceutical company Kitov Pharmaceuticals asked a New York federal judge on Friday to approve a $2 million deal to settle allegations the company and its CEO falsified late-stage trial results for a hypertension treatment and forced stocks to drop.
5 other articles on this case.
View all »